Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $165000.0.

  • aTYR PHARMA's Depreciation & Amortization (CF) fell 730.34% to $165000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $673000.0, marking a year-over-year decrease of 600.56%. This contributed to the annual value of $708000.0 for FY2024, which is 1800.0% up from last year.
  • aTYR PHARMA's Depreciation & Amortization (CF) amounted to $165000.0 in Q3 2025, which was down 730.34% from $166000.0 recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Depreciation & Amortization (CF) registered a high of $183000.0 during Q4 2023, and its lowest value of $39000.0 during Q4 2022.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $161000.0 (2023), whereas its average is $133578.9.
  • Per our database at Business Quant, aTYR PHARMA's Depreciation & Amortization (CF) crashed by 7067.67% in 2022 and then skyrocketed by 36923.08% in 2023.
  • Quarter analysis of 5 years shows aTYR PHARMA's Depreciation & Amortization (CF) stood at $133000.0 in 2021, then crashed by 70.68% to $39000.0 in 2022, then surged by 369.23% to $183000.0 in 2023, then fell by 4.37% to $175000.0 in 2024, then fell by 5.71% to $165000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $165000.0 in Q3 2025, compared to $166000.0 in Q2 2025 and $167000.0 in Q1 2025.